EDDI - Epigenetic Digital Data Interface

QBDC's innovative Epigenetic Characterization is delivered through its proprietary digital product, EDDI (Epigenetic Digital Data Interface). This cutting-edge tool revolutionizes biopharmaceutical development by providing unprecedented, real-time insights into cellular behavior, moving beyond traditional endpoint analyses.

EDDI works by continuously monitoring gene activation and epigenetic data, which are crucial indicators of a cell's health, activity, and "mood." This allows bioprocess scientists to effectively "listen" to their cells and translate these complex biological signals into actionable digital data.

Key benefits and features of EDDI for Epigenetic Characterization include:

• Real-time Cellular Insights: EDDI provides immediate and continuous feedback on how cells are performing under various bioprocess conditions. This allows for dynamic adjustments and ensures cells are operating at their peak efficiency.

• Eliminates Guesswork: By providing precise data on cellular states, EDDI replaces traditional trial-and-error approaches, significantly accelerating process development and troubleshooting.

• Precise Cell Characterization: The product enables a deep and accurate understanding of cell line behavior, stability, and responsiveness, which is critical for consistent and scalable biomanufacturing.

• Optimized Bioprocesses: EDDI facilitates the identification of optimal "working conditions" for cell cultures, allowing for the precise tuning of media components, environmental parameters, and feeding strategies for enhanced yields and desired product quality.

• Enhanced Product Quality & Consistency: By monitoring cellular stress and optimal states, EDDI helps maintain consistent product quality attributes throughout the manufacturing process, reducing batch variability.

Ultimately, EDDI as an epigenetic characterization product empowers biopharmaceutical companies to achieve more efficient, robust, and predictable biomanufacturing outcomes. QBDC is also at the forefront of integrating EDDI's rich epigenetic data with machine learning (ML) and artificial intelligence (AI) to develop sophisticated "digital twins," further advancing precision and control in the pharmaceutical industry.